Unveiling the Potential of VELScope in Potentially Malignant Oral Lesion Early Detection for Future Dental Diagnosis Technology
Main Article Content
Abstract
Introduction: Oral lesions range from innocuous to possibly dangerous, including oral cancer, which is the world's 16th most common malignancy. Early detection of oral cancer can enhance a patient's life expectancy by a decade, emphasizing the need of diagnostic instruments like VELScope. VELScope is a portable device that employs blue light to examine oral tissue, exposing natural fluorescence and emphasizing aberrant regions that would otherwise be invisible without the use of specialized equipment.
Objectives: This review looks at the possibility of the VELScope for identifying oral lesions, since it has the potential to be a future dental diagnostic tool.
Method: We began with 88 findings and reduced them down to 33 research regarding VELScope technology published in the previous five years. Following screening, we chose ten articles using the same criteria for all research.
Results: VELScope uses fluorescence to identify both obvious and concealed oral lesions, which is especially useful when collagen loss occurs in normal tissues. While using autofluorescence requires knowledge, it assists in analyzing margins in probable pre- malignant oral conditions. VELScope, despite its limitations, has promise for early cancer diagnosis as technology develops.
Conclusion: When utilized for early diagnosis, VELScope helps to reduce oral cancer mortality, reaching an 83% 5-year survival rate. While it has limits, continuous technical improvements have the potential to improve its accuracy, making it a vital tool for accurate early diagnosis and lowering oral cancer mortality.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Deo PN, Deshmukh R. Oral microbiome: Unveiling the fundamentals. J Oral Maxillofac Pathol. 2019;23(1):122–8.
II. El Toum S, Cassia A, Bouchi N, Kassab I. Prevalence and Distribution of Oral Mucosal Lesions by Sex and Age Categories: A Retrospective Study of Patients Attending Lebanese School of Dentistry. Int J Dent. 2018;2018:4030134.
III. WHO. Global oral health status report. Vol. 57, Dental Abstracts. 2022.
IV. International Agency for Research on Cancer. Globocan World Fact Sheet 2020. WHO chronicle. 2020. p. 1–2
V. Hook H. It’s not just about the teeth: The importance of screening for oral cancer and raising awareness. Vol. 28, BDJ Student. 2021. p. 28–9.
VI. Velscope. 48% increase in examination revenue. - Velscope®. 2023.
VII. Wang C, Qi X, Zhou X, Liu H, Li M. Diagnostic value of objective VELscope fluorescence methods in distinguishing oral cancer from oral potentially malignant disorders (OPMDs). Transl Cancer Res. 2022 Jun;11(6):1603–15.
VIII. Mat Lazim N, Kandhro AH, Menegaldo A, Spinato G, Verro B, Abdullah B. Autofluorescence Image-Guided Endoscopy in the Management of Upper Aerodigestive Tract Tumors. Int J Environ Res Public Health. 2022 Dec;20(1).
IX. Shah S, Waknis P, Saha A, Setiya S, Ratra T, Vaswani V. The use of Velscope to assess cellular changes occuring in oral premalignancy. J oral Biol craniofacial Res. 2020;10(2):99– 103.
X. Fourie J. VELscope: shedding light on its ideal application. South African Dent J. 2018;73:71–7.
XI. Farah CS, Kordbacheh F, John K, Bennett N, Fox SA. Molecular classification of autofluorescence excision margins in oral potentially malignant disorders. Oral Dis. 2018 Jul;24(5):732–40.
XII. Amirchaghmaghi M, Mohtasham N, Delavarian Z, Shakeri MT, Hatami M, Mosannen Mozafari P. The diagnostic value of the native fluorescence visualization device for early detection of premalignant/malignant lesions of the oral cavity. Photodiagnosis Photodyn Ther. 2018 Mar;21:19– 27.
XIII. Cânjău S, Todea DCM, Sinescu C, Pricop MO, Duma VF. Fluorescence influence on screening decisions for oral malignant lesions. Rom J Morphol Embryol = Rev Roum Morphol Embryol. 2018;59(1):203–9.
XIV. Leuci S, Coppola N, Turkina A, Bizzoca ME, Favia G, Spagnuolo G, et al. May VelScope Be Deemed an Opportunistic Oral Cancer Screening by General Dentists? A Pilot Study. J Clin Med. 2020 Jun;9(6).